Look for them to pick on drug prices again. Last time HRC spoke about the prices, Phama stocks dropped huge. prepare your self for another round of attacks. Past history shows Fed chair, Lemonhead and HRC has taken a toll on Ligand. Brace your self and don't let them steal your money.
the few minutes that I was correct was enough time for me. like I said it was my opinion and yes I was partly wrong. but hey I will take todays trading any day.
I know its hard for me to say since Ligand is one of my fav stocks, but you will see a down turn on Tuesday, we already see it after hours. I have been in this stock for the last 8 years its just the way it is.
Earnings will disappoint, and look for a 10 to 20% drop in stock price on the 10th. make sure you position your self. however this is my opinion make sure you do your own DD.
Don't get me wrong I like LGND but why are we positive today? I am surprised we did not drop 25% or more on this news? these type of stories kill this stock company
nice positive statement, how long have you been investing in bio's? the only thing I am worried about is the general market. Ligands 3rd quarter results may surprise all of us. people don't quit getting sick, no matter what the market brings.
panic sellers, Clinton isn't helping with her words on drug prices, crooks
As you know we have a good investment, this stock is well with over 100 pps nice pull back to pick up more shares. however we are well over due for some good news. over all the market is holding us back and Clinton isn't helping.
people panic too much here! why sell just because someone posted non value added article. they, may , when, where. sometime? nothing set in stone. sit back and collect cheap shares of LGND on others expense
45% annualized EPS growth over the next five years
Lastly, you'll find Ligand Pharmaceuticals among the fastest-growing biotech stocks with a projected annualized EPS growth rate of 45% over the coming five years. Wall Street believes Ligand can grow its EPS from a reported $1.52 in 2014 to well over $6 per share in 2018.
Ligand may not be able to match the exceptional growth rates offered by Pacira or Supernus, but it could be the most attractive of the three considering its diverse product portfolio:
Source: Ligand Pharmaceuticals.
Ligand's bread and butter includes multiple myeloma drug Kyprolis, for which it receives tiered royalties that increase from 1.5% up to $250 million in annual sales to 3% for anything above $750 million. Following its approval as a second-line treatment for multiple myeloma, Ligand should be set for a 3% minimum royalty within the next 12 months, by my best estimate. Ligand also receives royalties for Promacta, a medicine designed to increase the number of platelets in the blood.
What makes Ligand particularly intriguing is its Captisol technology, which improves the solubility and stability of active pharmaceutical ingredients. Ligand currently has more than 120 partnerships where its Captisol formulation technology is being utilized, meaning it has a boatload of royalty opportunities that could last for a long time.
The biggest risk I see with Ligand is the potential for sales lumpiness. For example, modeling revenue projections for Ligand is practically impossible, given its 120 partnerships and the royalties streaming in from each one. Looking at Ligand's sales over the course of a year, it seems likely that investors will see growth, but on a quarter-to-quarter basis Ligand's sales could be all over the place.
Of the three fastest-growing biotech stocks, this is the one I'd suggest investors most closely look into for their own portfolio.
Clinton doesn't have a chance! trump will send all stocks upward, Next thing you know it Clinton will load up on these stocks to help fight her presidential campaign
after doing some research typically the rate hike doesn't have much affect on Bio tech stocks. Look to Lgnd to post some good news soon. and watch out for next quarters earnings they may surprise us all. the up trend in the stock price is a tell tell sign.
who cares about the rate hike, people who are having to take loans dont have money in the stock market anyway, simple as that. its all B.S to bring the market down so big investors can pick up cheap shares. Ride it out LGND will continue strong over the next few months.